SYSTEMIC LUPUS ERYTHEMATOSUS

This study looks at whether the shingles vaccine is safe and works well for people with lupus. About 224 adults with lupus will receive either the vaccine or a placebo, and researchers will track lupus flare-ups and immune response for 24 weeks. The goal is to see if the vaccine …

This early-stage study tests an experimental drug called UB-VV410 in 21 adults with active lupus (SLE) or lupus kidney disease that hasn't improved with standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs th…

This study tests two drugs, inebilizumab and blinatumomab, in people with hard-to-treat lupus or rheumatoid arthritis. The goal is to see if they are safe and can control the disease. About 220 adults will take part. This is not a cure, but aims to reduce symptoms and improve qua…

This study tests a drug called belimumab in 350 adults recently diagnosed with lupus (within 2 years). The goal is to see if it can reduce disease activity and help patients feel better over 3 years. Participants receive the drug as a weekly injection under the skin, alongside th…

This study tests a new treatment using specially engineered immune cells (CAR-NK) from cord blood for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis that haven't improved with standard treatments. The goal is to see if a single infusion can safely …

This study is watching 300 people with active lupus who are taking anifrolumab to see how well it controls their disease and what side effects occur. Researchers will track remission rates, flare-ups, quality of life, and steroid use over 5 years. The goal is to understand the dr…

This study tests whether anifrolumab, a drug already used for lupus, can improve blood vessel function and reduce inflammation in the arteries of people with lupus. About 45 adults with lupus will receive either the drug or a placebo over 8 months. The goal is to see if this trea…

This early-stage study tests an investigational drug called ABBV-319 in about 36 adults with lupus or Sjogren's disease. The drug targets and depletes overactive B cells, which are immune cells that drive these autoimmune conditions. The main goals are to check safety, how the dr…

This early-stage study is testing a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of these specially designed immune cells. The m…

This early-stage study tests a new medicine called surovatamig in 48 adults with rheumatoid arthritis or lupus. The main goal is to check if the drug is safe and tolerable, and how the body processes it. Participants receive increasing doses to find the best and safest level.

This early-stage study tests a single injection of a new drug, LBL-047, in healthy adults and people with mild-to-moderate systemic lupus erythematosus (SLE). The main goal is to check safety and side effects, and to see how the drug moves through the body. About 112 participants…

This early-stage study tests the safety of a new drug called CPTX2309 in healthy people and those with moderate to severe rheumatoid arthritis or lupus. Researchers will give the drug through a vein and watch for side effects, changes in lab tests, and how the body responds. The …

This early-stage study tests a new treatment called HN2301 in 30 people with autoimmune diseases like lupus, scleroderma, or rheumatoid arthritis. The main goal is to check safety and find the right dose. Researchers will also look at how well the therapy works and how the body r…

This study looks at the long-term safety of a drug called ianalumab for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. It is for those who have already completed a previous ianalumab study. About 550 participants will receive either the drug or a pl…

This early-phase study tests whether a new drug, ONTO1, is safe and tolerable for people with lupus nephritis or systemic lupus erythematosus (SLE). Researchers will also see if adding ONTO1 to standard lupus treatments can improve symptoms. The study enrolls 61 adults with activ…

This study looks at whether people aged 60 and older with stable lupus can safely stop taking hydroxychloroquine, a drug that can harm the eyes over time. About 330 participants will either continue the drug or receive a placebo for one year. The goal is to see if stopping the dr…

This study tests a new treatment called anti-CD19/BCMA universal CAR-T cells for people with severe autoimmune diseases like lupus, scleroderma, and rheumatoid arthritis that haven't responded to standard therapies. The treatment uses specially engineered immune cells to target a…

This study tests a new medicine called RO7507062 in 70 people with systemic lupus erythematosus (SLE). The goal is to check its safety and how the body processes it. Participants receive the drug as a shot under the skin. This is an early-stage trial, so the main focus is on side…

This study tests a new treatment for people with lupus, scleroderma, or certain muscle diseases. The treatment uses a patient's own immune cells, modified to find and attack faulty B cells that drive the disease. About 24 adults will receive the therapy after a short course of ch…

This early-phase study tests a new mRNA drug called MTS109 in 15 people with moderate to severe autoimmune diseases like lupus and scleroderma. The main goal is to check safety and side effects, not to cure the disease. Participants receive the drug by IV and are monitored closel…

This early-phase study tests a new treatment called CABA-201 for people with active systemic lupus erythematosus (SLE), including those with kidney inflammation (lupus nephritis). The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells that dr…

This study tests a new drug called MIL62 for people with systemic lupus erythematosus (SLE), an autoimmune disease. About 316 adults with active lupus will receive either MIL62 or a placebo to see if the drug safely reduces disease activity and allows lower steroid doses. The mai…

This early-stage study tests a treatment called obecabtagene autoleucel (obe-cel) for people with severe lupus that hasn't responded to other therapies. Obe-cel uses a patient's own immune cells, modified to target and destroy faulty B cells that drive lupus. The main goals are t…

This study tests a weekly injection of anifrolumab in 245 adults with lupus who have not used strong immune-suppressing drugs before. The goal is to see if this treatment can help patients achieve remission and safely reduce or stop steroid use over 52 weeks. Participants must ha…

This study tests whether the drug telitacicept works better than the standard drug cyclophosphamide for lung scarring (interstitial lung disease) caused by lupus. About 100 adults with early lupus and lung changes on CT scans will take part. The main goal is to see if telitacicep…

This study tests if adding dapirolizumab pegol to standard lupus treatments can better control moderate to severe disease. About 450 adults with active lupus will receive the drug or a placebo for 48 weeks. The goal is to reduce lupus symptoms and flares without worsening overall…

This early-stage study tests a new drug, GSK4527363, for safety and how the body processes it. It includes healthy adults, people with active lupus, and those with lung scarring linked to connective tissue disease. The goal is to find safe dosing and check for side effects before…

This early-stage study tests whether a new drug called AZD5492 is safe and tolerable in 72 adults with lupus, myositis, or rheumatoid arthritis. Participants receive either one or two doses under the skin and are monitored for side effects and drug levels over 6 months. The goal …

This study tests a new drug called E6742 for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 256 adults will receive either E6742 or a placebo to see if the drug can reduce lupus symptoms while allowing lower steroid use. The main goal is to me…

This study tests a stem cell transplant in children and young adults (ages 8 to 25) with life-threatening lupus or scleroderma that hasn't responded to standard treatments. The goal is to wipe out the faulty immune system and replace it with the patient's own healthy stem cells, …

This early-stage trial tests a new cell therapy for children and young adults (ages 2-30) with severe lupus that hasn't responded to standard treatments. Doctors take a patient's own T cells, genetically modify them to target and destroy harmful B cells, and infuse them back. The…

This study tests an investigational drug called anifrolumab in children aged 5 to 17 with moderate to severe systemic lupus erythematosus (SLE), an autoimmune disease. The goal is to see if the drug can help control lupus activity when added to standard treatments. About 100 part…

This early-stage study tests a universal CAR T-cell therapy designed to target and destroy certain immune cells (those with CD19 or BCMA markers) that drive autoimmune diseases. It enrolls 12 adults with severe conditions like lupus, scleroderma, or vasculitis that have not respo…

This early-stage study tests a single injection of cells from donated umbilical cords in 10 adults with active lupus. The goal is to see if the treatment is safe and can improve kidney function and reduce disease activity when added to standard care. Participants will have regula…

This study tests an experimental drug called VENT-03 in 24 adults with active cutaneous lupus (skin lupus), with or without systemic lupus. Participants take VENT-03 or a placebo for 4 weeks, then everyone gets VENT-03 for 8 more weeks. The goal is to see if the drug reduces skin…

This early-stage study is testing a new drug called A-319 in 25 adults with active or treatment-resistant systemic lupus erythematosus (SLE). The drug is designed to target and help control overactive immune cells. The main goal is to check if it is safe and to see how the body r…

This early-stage study tests a new, fast-made version of CAR-T cell therapy for people with severe lupus that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and calm the overactive immune system causing lupus. The main g…

This study tests a new treatment for autoimmune diseases like lupus and scleroderma. It combines a special immune cell therapy (AD-PluReceptor NK cells) with a targeted drug (tafasitamab) and chemotherapy. The goal is to find a safe dose and see if it can control the disease. Abo…

This early-stage study tests a personalized cell therapy (CAR-T) for people with severe lupus that hasn't improved with standard treatments. The therapy uses the patient's own immune cells, modified to target and calm the overactive immune system. The goal is to safely reduce dis…

This early-stage study tests a new type of CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. The therapy uses a person's own immune cells, modified to target and calm the overactive immune system. The goal is to reduce disease activity…

This early-stage study is testing an experimental drug called GSK5926371 in people with autoimmune rheumatic diseases like lupus and rheumatoid arthritis. The drug works by helping the body's immune cells target and destroy certain immune cells that are causing the disease. The m…

This study tests a new drug called alnuctamab in 21 adults with moderate to severe lupus that hasn't improved with standard treatments. The goal is to see if the drug is safe and can help control the disease. Participants will receive the drug and be monitored for side effects an…

This early-phase study tests a new treatment called CC-97540, which uses a person's own immune cells (CAR T cells) to target and calm the overactive immune system in severe autoimmune diseases like lupus, myositis, scleroderma, and rheumatoid arthritis. The goal is to see if it i…

This study tests an experimental oral medicine, BI 3000202, in 405 adults with moderate to severe systemic lupus erythematosus (SLE). Participants are randomly assigned to one of four doses of BI 3000202 or a placebo, taken daily for a year, while continuing their usual lupus tre…

This study is for people who have both an autoimmune disorder (like rheumatoid arthritis, lupus, or multiple sclerosis) and advanced cancer that has spread or cannot be removed. It tests a drug called nivolumab, which helps the immune system fight cancer, given alone or with othe…

This early-stage study tests a new medicine called LY4298445 in healthy volunteers and people with lupus or rheumatoid arthritis. The main goal is to check safety and how the body handles the drug. About 63 participants will be followed for up to a year. This is not a cure; it ai…

This early-phase trial tests a new treatment called Meta10-19 for people with moderate to severe lupus. The treatment uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. The study aims to find a safe dose and see if it can cont…

This study tests a new medicine called SHR-2173 for people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 248 adults will receive either the drug or a placebo to see if it reduces disease activity without serious side effects. The main goal is…

This early-stage study is testing a new drug called budoprutug in 30 adults with active lupus who haven't responded well to other treatments. The main goal is to check if the drug is safe and how the body processes it. Researchers will also look for early signs that it might help…

This early-stage study tests a new, fast-made CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. The therapy uses a person's own immune cells, modified to target and calm the overactive immune system causing lupus. The main goals are to…

This study tests an online health program that teaches diet and self-care habits to 200 adults with conditions like rheumatoid arthritis, lupus, or psoriatic arthritis. The goal is to see if the program can reduce fatigue and improve quality of life. Participants will complete su…

This early-stage study tests a new medicine called MK-1045 in about 21 people with lupus or rheumatoid arthritis. The main goal is to check if the drug is safe and well-tolerated at different doses. Researchers will also measure how the drug moves through the body. This is a Phas…

This study watches about 3,200 adults with moderate-to-severe lupus to see if those taking the drug anifrolumab have more serious infections or cancers than those on standard treatments. Researchers will look at medical records over time, but no new treatments or tests are given.…

This study follows about 442 pregnant women with moderate-to-severe lupus to see if taking the drug anifrolumab during pregnancy affects the health of mothers or their babies. Some women took the drug while pregnant, and others did not. The goal is to gather safety information, n…

This study is testing a new educational tool designed for people with melanoma who also have an autoimmune disease (like rheumatoid arthritis or Crohn's disease). The tool helps patients understand immune checkpoint inhibitor drugs and their possible side effects. Researchers wil…

This study aims to create a new, objective way to measure pain in children with juvenile idiopathic arthritis, lupus, or fibromyalgia. Researchers will collect data from 90 participants over one year to see if this pain measurement can help doctors choose the right treatment fast…

This study tests a program called CO-LEAD that helps doctors and patients with lupus talk more effectively about medications. The goal is to improve how often patients take their medicine as prescribed. About 480 patients and their doctors will take part, and researchers will lis…

This study looks at why some lupus patients get false positive results on tests for anti-HLA antibodies, which can make it harder to get an organ transplant. Researchers will check how common these false positives are in 30 lupus patients who have no other risk factors. They also…

This study is building a large collection of health information and blood samples from 5,000 adults with rheumatic diseases like rheumatoid arthritis, lupus, and scleroderma. Researchers will use this data to find links between patient outcomes and biological markers. The goal is…

This study aims to learn more about how lupus (SLE) starts and progresses by observing patients and their relatives over time. Researchers will collect medical histories, blood and urine samples, and genetic material to identify factors that influence the disease. Up to 2000 part…

This study is a registry that will enroll up to 1,000 pregnant women or those planning pregnancy who have autoimmune diseases like lupus or rheumatoid arthritis. Researchers at Duke University will collect information to identify risk factors for poor pregnancy outcomes. The goal…

This study looks at how changes in the TREX1 gene are linked to lupus, especially skin problems. Researchers will study 90 adults with lupus to see if certain gene patterns relate to more severe disease. No new treatments are tested; the goal is to better understand the disease.

This study looks at how much of the lupus drug anifrolumab passes into breast milk and into the baby's blood. Researchers will collect milk and blood samples from 16 breastfeeding mothers with lupus who are already taking anifrolumab. The goal is to better understand the safety o…

This study is creating a registry of 1000 people with lupus (systemic lupus erythematosus or cutaneous lupus) seen at Duke University. Researchers will collect medical information and blood samples over time to better understand how lupus changes and improve future treatments. Pa…

This study is creating a tool to help doctors diagnose and choose treatments for autoimmune diseases. Researchers will analyze blood and other samples from 500 children with autoimmune conditions and healthy children to find patterns in genes and proteins. The goal is to better u…

This study looks at whether the immune system ages faster in people with lupus. Researchers will measure specific immune cells and telomeres in 75 adults aged 18-60 with lupus. The goal is to understand the aging process, not to test a new treatment.

This study tracks 240 pregnant women with lupus who have taken the drug anifrolumab during pregnancy or shortly before conception. Researchers will monitor for birth defects and other pregnancy complications to better understand the drug's safety. The goal is to gather informatio…

This study is a long-term registry for people with lupus (SLE) who are under a rheumatologist's care. Researchers will collect information during regular doctor visits to learn more about how the disease behaves and how well current treatments work in the real world. No experimen…